The Nontuberculous Mycobacterial (NTM) Infections market report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of opportunities and assess the underlying potential of the market.
Nontuberculous Mycobacterial (NTM) Infections: An Overview
According to the American Lung Association, Nontuberculous mycobacteria (NTM) are naturally occurring organisms found in water and soil. NTM lung infection occurs when a person inhales the organism from their environment. Most people do not become ill but for some susceptible individuals, the slowly progressive and destructive disease can occur.
Similar to TB, NTM infections can occur throughout the body. However, pulmonary infections, lymphadenitis, and skin and soft tissue infections are the most commonly described attributable human infections with lung infections attracting the greatest amount of attention in recent times.
Nontuberculous Mycobacterial (NTM) Infections Market Key Facts
As per Delveinsight’s estimates, in 2017, the total NTM prevalence in 7MM was reported to be 365,200+ cases. Moreover, the total prevalence of NTM infections in the united states was estimated to be 179,000+ cases in 2017.
The disease was more prevalent among the elderly with a median age of 66 [range 12 to 92 years] and was most commonly due to Mycobacterium Avium Complex (MAC) as per studies conducted by Kendall et al. 2013.
According to Johnson and Odell. 2014, “in patients greater than 65 years the prevalence was 47 per 100,000 patient years. Women were more likely to have NTM disease than men, the disease prevalence increased with age, and it was more common in the West and Southeast regions.”
Nontuberculous Mycobacterial (NTM) Infections Market
Nontuberculous Mycobacterial (NTM) Infections market size is expected to increase during the forecast period owing to the launch of upcoming therapies.
The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Nontuberculous Mycobacterial (NTM) Infections market size by analyzing the impact of current and emerging therapies in the market. It also provides a detailed assessment of the market drivers & barriers, unmet needs, and emerging technologies.
The report gives a thorough detail of the Nontuberculous Mycobacterial (NTM) Infections market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MoA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.
Nontuberculous Mycobacterial (NTM) Infections Epidemiology
The epidemiology section covers insights into the historical and current Nontuberculous Mycobacterial (NTM) Infections patient pool and forecasted trends for every seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Nontuberculous Mycobacterial (NTM) Infections Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Nontuberculous Mycobacterial (NTM) Infections market or expected to get launched in the market during the study period. The analysis covers Nontuberculous Mycobacterial (NTM) Infections market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The report also covers the Nontuberculous Mycobacterial (NTM) Infections Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for emerging therapies.
Request for Sample PDF Report – https://www.delveinsight.com/sample-request/nontuberculous-mycobacterial-ntm-infections-market
Nontuberculous Mycobacterial (NTM) Infections Therapeutics Analysis
The Nontuberculous mycobacteria (NTM) market dynamics is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, rising awareness of the disease, incremental healthcare spending across the world and the expected launch of emerging therapies.
Some of the key companies in the Nontuberculous Mycobacterial (NTM) Infections Market include:
RevImmune
Redhill Biopharma
Novoteris
Savara Pharma
Merck Sharp & Dohme Corp.
And many others.
Nontuberculous Mycobacterial (NTM) Infections Therapies covered in the report include:
Emend
CYT107 IL-7
RHB-204
Molgramostim
Nitric Oxide
Thiolanox
And many more.
Get More Detailed Insights Into the Emerging Therapies & Key Companies – https://www.delveinsight.com/sample-request/nontuberculous-mycobacterial-ntm-infections-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Nontuberculous Mycobacterial (NTM) Infections Competitive Intelligence Analysis
4. Nontuberculous Mycobacterial (NTM) Infections Market Overview at a Glance
5. Nontuberculous Mycobacterial (NTM) Infections Disease Background and Overview
6. Nontuberculous Mycobacterial (NTM) Infections Patient Journey
7. Nontuberculous Mycobacterial (NTM) Infections Epidemiology and Patient Population
8. Nontuberculous Mycobacterial (NTM) Infections Treatment Algorithm, Current Treatment, and Medical Practices
9. Nontuberculous Mycobacterial (NTM) Infections Unmet Needs
10. Key Endpoints of Nontuberculous Mycobacterial (NTM) Infections Treatment
11. Nontuberculous Mycobacterial (NTM) Infections Marketed Products
12. Nontuberculous Mycobacterial (NTM) Infections Emerging Therapies
13. Nontuberculous Mycobacterial (NTM) Infections Seven Major Market Analysis
14. Attribute Analysis
15. Nontuberculous Mycobacterial (NTM) Infections Market Outlook (7 major markets)
16. Nontuberculous Mycobacterial (NTM) Infections Access and Reimbursement Overview
17. KOL Views on the Nontuberculous Mycobacterial (NTM) Infections Market.
18. Nontuberculous Mycobacterial (NTM) Infections Market Drivers
19. Nontuberculous Mycobacterial (NTM) Infections Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF Report – https://www.delveinsight.com/sample-request/nontuberculous-mycobacterial-ntm-infections-market
Other Latest Reports By DelveInsight
Food Allergy Market
DelveInsight’s “Food Allergy Market” report delivers an in-depth understanding of the Food Allergy, historical and forecasted epidemiology as well as the Food Allergy market size, share, and trends in the 7MM.
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Shruti ThakurEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/
